Karl-Erik Andersson to Prostatic Hyperplasia
This is a "connection" page, showing publications Karl-Erik Andersson has written about Prostatic Hyperplasia.
Connection Strength
2.089
-
Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011 Mar; 30(3):292-301.
Score: 0.326
-
Andersson KE. How many drugs for LUTS due to BPH are too many? J Urol. 2008 Sep; 180(3):811-2.
Score: 0.273
-
Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007 Oct; 26(6 Suppl):928-33.
Score: 0.258
-
Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol. 2002 Apr; 19(6):390-6.
Score: 0.176
-
Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002 Apr; 19(6):397-404.
Score: 0.176
-
Andersson KE, Chapple CR, Höfner K. Future drugs for the treatment of benign prostatic hyperplasia. World J Urol. 2002 Apr; 19(6):436-42.
Score: 0.176
-
Lombardo R, Andersson KE, Tubaro A, De Nunzio C. Intraprostatic injections for lower urinary tract symptoms/benign prostatic enlargement treatment. Minerva Urol Nefrol. 2018 Dec; 70(6):570-578.
Score: 0.139
-
De Nunzio C, Roehrborn CG, Andersson KE, McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms. Eur Urol Focus. 2017 10; 3(4-5):352-363.
Score: 0.131
-
Kurizaki Y, Ishizuka O, Imamura T, Ishikawa M, Ichino M, Ogawa T, Nishizawa O, Andersson KE. Relationship between expression of ß3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013 Jan; 32(1):88-91.
Score: 0.089
-
Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson KE. Relation between expression of a(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011 Feb; 45(1):15-9.
Score: 0.080
-
Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson KE, Hedlund P. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010 May; 57(5):902-10.
Score: 0.074
-
Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007 Oct; 26(6 Suppl):948-54.
Score: 0.065
-
Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007 Jul; 4(7):368-78.
Score: 0.063
-
Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology. 2003 Nov; 62(5 Suppl 2):3-10.
Score: 0.049
-
Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB, Marini M, Gelmini S, Fibbi B, Donati S, Villari D, Forti G, Colli E, Andersson KE, Maggi M. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab. 2005 Feb; 90(2):962-72.
Score: 0.013